Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and DaVita (NYSE:DVA – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
Profitability
This table compares Lisata Therapeutics and DaVita's net margins, return on equity and return on assets.
Get Lisata Therapeutics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
| DaVita | 4.83% | 74.02% | 3.67% |
Valuation & Earnings
This table compares Lisata Therapeutics and DaVita's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.26 |
| DaVita | $11.61 billion | 0.61 | $560.40 million | $5.78 | 13.53 |
DaVita has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
6.0% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 86.5% of DaVita shares are owned by institutional investors. 2.2% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 1.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility & Risk
Lisata Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, DaVita has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Lisata Therapeutics and DaVita, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| DaVita | 1 | 5 | 1 | 0 | 2.00 |
Lisata Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 373.19%. DaVita has a consensus target price of $86.43, indicating a potential upside of 10.52%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Lisata Therapeutics is more favorable than DaVita.
Summary
DaVita beats Lisata Therapeutics on 8 of the 13 factors compared between the two stocks.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
About DaVita
(Get Rating)
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.